CAMBRIDGE, Mass., March 26, 2018 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnologycompany developing IPI-549, a potentially first-in-class immuno-oncology product candidate that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma), today announced that management will be presenting at the following two upcoming conferences:
Needham & Company Annual Healthcare Conference:
8th Annual Cancer and Immunotherapy Conference: Jeffery Kutok, M.D., Ph.D., Infinity's Chief Scientific Officer, will present during the "The Tumor Microenvironment in Cancer: Reevaluating Checkpoints on Suppressive Myeloid Cells," session at the 8th Annual Cancer and Immunotherapy Conference hosted by William Blair & Company and MaidStone Life Sciences on April 5, 2018, at 10:40 a.m. ET at the Apella Event Space Alexandria Center, New York, NY.
About InfinityInfinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is advancing IPI-549, an oral immuno-oncology development candidate that selectively inhibits PI3K-gamma. A Phase 1/1b study in approximately 200 patients with advanced solid tumors is ongoing. For more information on Infinity, please refer to Infinity's website at www.infi.com.
Contact:Stephanie Ascher, Stern Investor Relations, Inc.212-362-1200 or Stephanie@sternir.com
View original content:http://www.prnewswire.com/news-releases/infinity-to-present-at-two-upcoming-conferences-300619141.html
SOURCE Infinity Pharmaceuticals, Inc.
Subscribe to our Free Newsletters!